20 July 2023 - As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products ...
5 June 2023 - Today, CADTH is communicating a series of improvements that will further our ambition to innovate in ...
1 September 2022 - CADTH is pleased to announce the launch of its new post-market drug evaluation program. ...
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
21 November 2019 - CADTH has undertaken an internal review and established a novel process for the review of cell and ...
12 December 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the submission and ...
27 November 2017 - The CADTH Common Drug Review is aligning the process for secure file sharing with the pan-Canadian ...
13 November 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission requirements ...
11 October 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the resubmission ...
28 September 2017 - In September 2016, CADTH updated the advance notification procedure for the Common Drug Review. ...
1 August 2017 - Given the type of data required to support biosimilar authorization differs from that required for a biologic ...
13 July 2017 - CADTH is inviting stakeholder comments and feedback on proposed revisions to the Procedure for the CADTH Common ...
13 June 2017 - In November 2016, CADTH invited stakeholder comments and feedback on a proposed process for the assessment ...
9 June 2017 - In order to reflect the current environment for subsequent entry non-biological complex drugs, CADTH, in consultation ...
17 April 2017 - In collaboration with the participating jurisdictions, CADTH is pleased to announce that it will accept submissions ...